Arthur Tutela, MD
Ophthalmology · West Orange, NJNPI 1144257155
Payments from drug & device makers
Across 165 payments — averaging $27.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$2K
- AbbVie$612
- Johnson & Johnson Surgical Vision, Inc.$488
- Sun Pharmaceutical Industries Inc.$376
- Novartis$314
- Aerie Pharmaceuticals, Inc.$195
- plus $882 from 12 others
What the payments were for
- Food & beverage$4,55699%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 14 | $1,737 |
| AbbVie(2 entities) | 44 | $612 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $488 |
| Sun Pharmaceutical Industries Inc. | 28 | $376 |
| Novartis | 30 | $314 |
| Aerie Pharmaceuticals, Inc. | 6 | $195 |
| Dompe US, Inc. | 2 | $173 |
| Sight Sciences, Inc. | 2 | $155 |
| Bausch & Lomb Americas Inc. | 9 | $145 |
| Oyster Point Pharma, Inc. | 5 | $71 |
| Genentech USA, Inc. | 2 | $61 |
| Kala Pharmaceuticals, Inc. | 4 | $56 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $55 |
| Alcon | 3 | $53 |
| Apellis Pharmaceuticals, Inc. | 2 | $39 |
| Eyevance Pharmaceuticals LLC | 2 | $31 |
| Amgen | 1 | $28 |
| Tarsus Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$287
- Photrexa$287
- iDoseTR$194
- iStent Infinite$194
- iStent inject W$153
- KXL System$153
- OMNI(R) SURGICAL SYSTEM (US)$140
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$139
- iStent infinite Trabecular Micro-Bypass System Model iS3$139
- Rhopressa$124
- Rocklatan$124
- Oxervate$124
- Tecnis Simplicity$120
- iStent inject Trabecular Micro-Bypass Stent System$109
How this compares
$4,603 in reported general payments places this provider in the 75th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 147 | $197,632 |
| MieboPerfluorohexyloctane/Pf | 86 | $88,349 |
| RestasisCyclosporine | 56 | $65,040 |
| LumiganBimatoprost | 102 | $51,465 |
| RocklatanNetarsudil Mesylat/Latanoprost | 81 | $48,224 |
| VyzultaLatanoprostene Bunod | 116 | $44,171 |
| CequaCyclosporine | 53 | $36,046 |
| CombiganBrimonidine Tartrate/Timolol | 39 | $17,050 |
| Alphagan PBrimonidine Tartrate | 21 | $11,711 |
| RhopressaNetarsudil Mesylate | 16 | $11,679 |
| Cyclosporine | 19 | $10,935 |
| Prednisolone Acetate | 179 | $8,734 |
| TyrvayaVarenicline Tartrate | 13 | $8,357 |
| IyuzehLatanoprost/Pf | 27 | $8,107 |
| Latanoprost | 637 | $5,426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $145 | $330,152349 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $612 | $145,266218 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $195 | $59,90497 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $376 | $36,04653 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $71 | $8,35713 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $55 | $3,54221 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $31 | $2,94713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in West Orange
- Janet NeigelWest Orange$90K
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Luis Gonzalez GonzalezTeaneck$727K
- Cynthia MatossianPennington$726K
- Charles CraneSouth Orange$582K
- Albert KhouriNewark$542K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.